Annual Cash & Cash Equivalents
$292.42 M
+$35.17 M+13.67%
December 31, 2022
Summary
- As of February 10, 2025, RXDX annual cash & cash equivalents is $292.42 million, with the most recent change of +$35.17 million (+13.67%) on December 31, 2022.
- During the last 3 years, RXDX annual cash & cash equivalents has risen by +$287.97 million (+6471.30%).
Performance
RXDX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$113.34 M
-$179.08 M-61.24%
March 31, 2023
Summary
- As of February 10, 2025, RXDX quarterly cash and cash equivalents is $113.34 million, with the most recent change of -$179.08 million (-61.24%) on March 31, 2023.
- Over the past year, RXDX quarterly cash and cash equivalents has dropped by -$113.69 million (-50.08%).
Performance
RXDX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
RXDX Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +13.7% | -50.1% |
| 3 y3 years | +6471.3% | - |
| 5 y5 years | +6471.3% | - |
RXDX Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | -12.0% | -61.2% | -30.8% |
| 5 y | 5-year | at high | -98.5% | -63.6% | -52.2% |
| alltime | all time | at high | -98.5% | -63.6% | -52.2% |
Prometheus Biosciences Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2023 | - | $113.34 M(-61.2%) |
| Dec 2022 | $292.42 M(+13.7%) | $292.42 M(+272.9%) |
| Sep 2022 | - | $78.41 M(-18.3%) |
| Jun 2022 | - | $95.96 M(-57.7%) |
| Mar 2022 | - | $227.03 M(-11.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2021 | $257.25 M(+374.6%) | $257.25 M(-7.8%) |
| Sep 2021 | - | $279.12 M(-8.3%) |
| Jun 2021 | - | $304.39 M(-2.2%) |
| Mar 2021 | - | $311.23 M(+474.2%) |
| Dec 2020 | $54.20 M(+1118.0%) | $54.20 M |
| Dec 2019 | $4.45 M | - |
FAQ
- What is Prometheus Biosciences annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Prometheus Biosciences?
- What is Prometheus Biosciences annual cash & cash equivalents year-on-year change?
- What is Prometheus Biosciences quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Prometheus Biosciences?
- What is Prometheus Biosciences quarterly cash and cash equivalents year-on-year change?
What is Prometheus Biosciences annual cash & cash equivalents?
The current annual cash & cash equivalents of RXDX is $292.42 M
What is the all time high annual cash & cash equivalents for Prometheus Biosciences?
Prometheus Biosciences all-time high annual cash & cash equivalents is $292.42 M
What is Prometheus Biosciences annual cash & cash equivalents year-on-year change?
Over the past year, RXDX annual cash & cash equivalents has changed by +$35.17 M (+13.67%)
What is Prometheus Biosciences quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of RXDX is $113.34 M
What is the all time high quarterly cash and cash equivalents for Prometheus Biosciences?
Prometheus Biosciences all-time high quarterly cash and cash equivalents is $311.23 M
What is Prometheus Biosciences quarterly cash and cash equivalents year-on-year change?
Over the past year, RXDX quarterly cash and cash equivalents has changed by -$113.69 M (-50.08%)